Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Cluster Headache Syndrome (Cluster Headache). According to GlobalData, Phase II drugs for Cluster Headache Syndrome (Cluster Headache) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lysergic acid diethylamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lysergic acid diethylamide overview

Lysergic acid diethylamide is under development for the treatment of anxiety disorders, cluster headaches, acute and chronic pain and psychiatric disorders such as major depression disorder, generalized anxiety disorders. It is a psychedelic drug. It is administered through oral route. The drug candidate acts by targeting 5-hydroxytryptamine receptor 2A (5HT2A). It is developed based on Zydis orally disintegrating tablet (ODT) technology.

It was under development for the treatment of attention deficit hyperactivity disorder (ADHD).

Mind Medicine MindMed overview

Mind Medicine MindMed (MindMed) is a pharmaceutical drug development and clinical research company. The company develops medicinal products to treat brain health disorders, psychiatry, pain and substance use disorders, and related therapeutic areas. Its product offerings include psychedelic and empathogen drugs. The company offers research and development supports such as non-clinical, pre-clinical, human clinical trials and investigator-initiated trials. It also develops drugs support clinical data opportunity in autism spectrum disorders (ASD), address a critical gap in opioid use disorder (OUD) treatment. MindMed is headquartered in New York, the US.

For a complete picture of Lysergic acid diethylamide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.